Golden State Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-30,000
Closed -$236K – 1580
2026
Q2
$236K Buy
+30,000
New +$147K 0.02% 396

Other funds holding ABCL

Golden State Wealth Management's ABCL Position: Q3 2026 in Review

Golden State Wealth Management sold out of AbCellera Biologics (ABCL) in Q3 2026, closing a stake of 30,000 shares — an estimated $236K sold.

Golden State Wealth Management first reported a position in ABCL in Q2 2026 and held it in 1 quarter. The position peaked at $236K in Q2 2026. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Golden State Wealth Management reported no remaining AbCellera Biologics position as of Q3 2026 after selling out during the quarter.
  • Golden State Wealth Management sold 30,000 AbCellera Biologics shares in Q3 2026, an estimated $236K.
  • Golden State Wealth Management first reported a position in AbCellera Biologics in Q2 2026 and held it in 1 quarter.
  • Golden State Wealth Management's AbCellera Biologics position peaked at $236K in Q2 2026.
  • 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Golden State Wealth Management's 13F filing for Q3 2026, filed 2 Nov 2026.